Mary T. Brophy MD
Assistant Professor, Hematology & Medical Oncology
150 S Huntington Avenue | (617) 638-7523mary.brophy@va.gov
mtbrophy@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Education
MD, Tufts University School of Medicine
BS, Stonehill College
Publications
Kim DY, Swetter SM, Huhmann L, Ferguson JM, Breglio K, Spence AC, Wheless L, Brophy MT, Do NV, Fillmore N, Hartman RI. Sentinel Lymph Node Biopsy Utilization and Positivity in Veterans with Cutaneous Melanoma: A Comparative Analysis of the VA Cancer Registry and the SEER Program. J Am Acad Dermatol. 2026 May 25. PMID: 42190751.
Published on 4/2/2026Ryu J, La J, Patell R, Li A, Do N, Brophy M, Fillmore N, Zwicker JI. Survival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis. Haematologica. 2026 Apr 02. PMID: 41924910.
Published on 4/1/2026He T, Betensky RA, Osorio RS, Swinnerton K, Zheng C, Jacobs T, Vedvyas A, Marsh K, Chodosh J, Hwang UY, Sifnugel N, Bubu OM, Wisniewski T, Brophy M, Do NV, Fillmore NR, Ramos-Cejudo J. Neutrophil inflammation metrics are associated with the risk of future dementia in large data from NYU Langone Hospitals and the Veterans Health Administration. Alzheimers Dement. 2026 Apr; 22(4):e71335. PMID: 41930609.
Published on 3/30/2026Goryachev SD, Wu JT, Lin E, Friedman DR, Zwolinski R, Dhond R, Elbers DC, La J, Yildirim C, Corrigan JK, Chen DCR, Brophy MT, Do NV, Fillmore NR. Rule-based natural language processing to extract clinical trial and research study enrollment history from unstructured notes. Health Informatics J. 2026; 32(1):14604582261430614. PMID: 41912375.
Published on 2/12/2026Hwang JC, Huhmann LB, Perez D, Kim DY, Nannini K, Do NV, Gaziano JM, Brophy MT, Wheless LE, Fillmore NR, Hartman RI. Parkinson's disease and risk of melanoma in United States veterans: A Veterans Affairs Cancer Registry retrospective cohort study. J Am Acad Dermatol. 2026 Jun; 94(6):1811-1814. PMID: 41690486.
Published on 1/2/2026Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB. Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2026 Jan 02; 9(1):e2551231. PMID: 41543856.
Published on 1/1/2026Cooperberg MR, Bihn JR, Culnan JM, La J, Goryachev SD, Chen DCR, Soloviev O, Lee G, Corrigan JK, Swinnerton KN, Nickols NG, Dulberger KN, Barata P, Bitting RL, Brophy MT, Cheng HH, De Hoedt A, Do NV, Freedland SJ, Garraway IP, Gaziano JM, Halabi S, Hauger RL, Loeb S, Nanus DM, Rebbeck TR, Rettig MB, Pan CX, Myrie K, Ramoni RB, Fillmore NR, Paller CJ. Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance. JAMA Oncol. 2026 Jan 01; 12(1):111-113. PMID: 41264314.
Published on 12/14/2025Wheeler AM, Ourada TJ, Jones SQ, Duryee MJ, England BR, Reynolds RJ, O'Dell JR, Newcomb J, Pillinger MH, Terkeltaub R, Ferguson R, Brophy M, LaMoreaux B, Merriman TR, Mikuls TR. Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy. Rheumatology (Oxford). 2025 Dec 14. PMID: 41390970.
Published on 11/20/2025Tosi HM, Zheng C, Tarren AH, Yellanki M, Miller SJ, Soloviev OV, Corrigan JK, Schneeloch GR, Katki HA, Kearney LE, Caverly TJ, Tanner NT, Wiener RS, Brophy M, Fillmore NR, Do NV, Elbers DC. Rapid Support and Implementation of an Application for the Prediction Augmented Screening Initiative (PASI) Planning Phase Through the Enabling Technologies for Rapid Learning Health Systems Platform (ENTHRALL) at the Department of Veterans Affairs (VA). Cancer Inform. 2025; 24:11769351251389781. PMID: 41281611.
Published on 11/20/2025Ferri GM, Yildirim C, Do NV, Brophy MT, Munshi NC, Edwards CV, Fillmore NR. Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma. EJHaem. 2025 Dec; 6(6):e70153. PMID: 41278511.